%0 Journal Article
%A Williams, Dylan M
%A Bandres-Ciga, Sara
%A Heilbron, Karl
%A Hinds, David
%A Noyce, Alastair J
%T Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.
%D 2020
%U http://hdl.handle.net/10668/16149
%X Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid-lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein-A5 or Apolipoprotein-C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020;88:1043-1047.
%K Anticholesteremic Agents
%K Apolipoprotein A-V
%K Apolipoproteins B
%K Cholesterol, LDL
%~